Fig. 18
From: Protein degradation technology: a strategic paradigm shift in drug discovery
Chemical structures of taselisib, GDC-0077, imatinib, masitinib, and PF-956980. Taselisib and GDC-0077 can induce the selective degradation of mutant p110α. Imatinib and masitinib can induce the downregulation of wild-type c-Kit at 2 μM concentration